By Andrew MacAskill, Maggie Fick and Bhanvi Satija LONDON, Jan 26 (Reuters) - UK-based drugmakers AstraZeneca and GSK will ...

Astrazeneca (AZN) closed the most recent trading day at $94.23, moving +1.38% from the previous trading session. The stock ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New ...

AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

AstraZeneca could build a new six-storey block at Cambridge Biomedical Campus (CBC) to house offices and a conference centre.

Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, ...

AstraZeneca is keeping its options over expansion in Cambridge open by submitting fresh plans for a new conference centre and ...